Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01466088 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
A Phase 2 study of Alzheimers Disease, sponsored by Targacept.
- Completed
- Registry status
- Phase 2
- Development phase
- 386
- Enrollment target
- 20
- Study locations
NCT01466088 is a Phase 2 study of Alzheimers Disease that has completed, run by Targacept. The registered enrollment target is 386 participants, below the 4,059-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT01466088, a Phase 2 study of Alzheimers Disease, has completed, sponsored by Targacept.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 386 participants
- Enrollment target
- 20
- Study locations
Study Summary
Alzheimer's disease is the most common form of dementia and is the fourth leading cause of death among people 65 years of age and older. The global prevalence of the disease will increase significantly as the population ages, unless preventative treatments can be identified and marketed. The present study seeks to evaluate AZD3480 (TC-1734) compared to an approved medication (donepezil) shown to improve cognition and function in patients with Alzheimer's disease.
Conditions Studied
Interventions
- DRUG Donepezil
- DRUG AZD3480
Study Locations (20)
Other
- Policlinic - Choceň
- BRAIN-SOULTHERAPY s.r.o. - Kladno
- Bialbi.s.r.o. Psychiatrické oddělení - Litoměřice
- Psychiatricka Ambulance - Olomouc
- Vojenska Nemocnice Psychiatricke oddeleni - Olomouc
- Clintrial - Prague
- PRAGTIS s.r.o. - Prague
- Psychosocialni centrum - Přerov
- Crucea Alba - Dr. Oros si Asociatii - Societate Civila Medicala - Oradea
- Spitalul de Psihiatrie Sibiu - Sibiu
- Spitalul Clinic Judetean de Urgenta SIBIU - Sibiu
- Spitalul Clinic Judetean de Urgenta, Clinica Psihiatrie - Timișoara
- Spitalul Clinic Judetean de Urgenta, Clinica Neurologie 2 - Timișoara
- Neurologicka Ambulancia, s.r.o. - Banská Bystrica
- Univerzitna nemocnica Bratislava, Geronto-psychiatrické oddelenie - Bratislava
- KONZILIUM s.r.o. - Dubnica nad Váhom
- Neurologická ambulancia - Krompachy
Florida
- Meridien Research - Brooksville
- MD Clinical - Hallandale
Arizona
- Banner Alzheimer Institute - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01466088
The ClinicalTrials.gov registry entry for NCT01466088 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 386 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,059-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (90% lower). The listed sponsor is Targacept, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Donepezil is the first listed.
NCT01466088 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01466088 about?
NCT01466088 is a clinical study titled "Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)". Alzheimer's disease is the most common form of dementia and is the fourth leading cause of death among people 65 years of age and older. The global prevalence of the disease will increase significantly as the population ages, unless preventative treatments can be identified and marketed. The present...
What is the current status of trial NCT01466088?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 386 participants. The study started on 2011-10. Estimated completion is 2014-05.
What conditions does trial NCT01466088 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT01466088?
The interventions under investigation include: Donepezil (DRUG), AZD3480 (DRUG).
Who is sponsoring clinical trial NCT01466088?
This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01466088 being conducted?
This trial has 20 study locations across Arizona, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.